New Biotechnology Books

Two new biotechnology books due out in March 2008:

[AMAZONPRODUCT=0973467673]
Best Practices in Biotechnology Education
22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups

First Edition, March 2008
Perfect Bound, 342 pages, US$74.95
ISBN: 978-09734676-7-3
Best Practices in Biotechnology Education is directed at faculty seeking to start or expand biotechnology education programs; policy-makers and economic developers seeking to help meet workforce needs; and, students, scientists, and business professionals looking to enter the industry or upgrade their existing skills.
The cases herein describe a wide variety of programs from high school through Ph.D. programs. Some are in their first years, whereas others are quite mature and have diversified to offer myriad degree and certificate options. There is also strong international representation, with programs from Australia, Canada, New Zealand, South Africa, and the United States.

[AMAZONPRODUCT=0973467606]

Best Practices in Biotechnology Business Development
Valuation, Licensing, Cash Flow, Pharmacoeconomics, Market Selection, Communication, and Intellectual Property

First Edition, March 2008
Perfect Bound, 186 pages, US$67.95
ISBN: 978-09734676-0-4
Seeking to meet the need to understand how to practice the business of biotechnology, these best practices provide a framework upon which to understand critical issues in biotechnology business development. Experts from a wide range of disciplines have composed best practices based on their experiences and expertise, creating a vital toolbox covering a broad spectrum of topics. These best practices will enable you develop a better understanding of the key elements in these operations and empower you to better manage their implementation

For more information, contact info@thinkbiotech.com.

0 Comments/

0 Likes

/0 Tweets/in Biotechnology Book Reviews, General Biotechnology

January 14, 2008

14 Jan 2008

Want biotechnology venture capital? Use a shotgun!

On returning from a meeting with a small biotechnology firm in which I serve on the advisory board, I was reminded of a novel strategy for attracting venture capital.

One of the challenges is attracting investment is finding an investor aligned with your company’s future directions. Venture capitalists may be interested only in large companies, in small companies, in diagnostic firms, in drug development, etc. One of the challenges, and opportunities, for small firms, is that their future is very uncertain. This makes it difficult to decide how to pitch the company to potential investors, but it also makes it possible to pitch more than one version of the company.

Using a shotgun approach, it is possible to craft several business plans built a common set of resources, each aimed at a different kind of investor, and simultaneously pitch these different plans to appropriate VCs. The reality is that most investors will realize that there is a great deal of flexibility in the business plan, because there are so many unknown elements in a young company, and pitching more investors increases the likelihood of attracting an investment.

0 Comments/

2 Likes

/0 Tweets/in General Biotechnology

January 7, 2008

07 Jan 2008

Journal of Commercial Biotechnology – January 2008

After months of work, the January issue of the Journal of Commercial Biotechnology, my first as managing editor, has just been published. The links below will take you to each article:

Volume 14, Issue 1

Editorial

Editorial	PDF
Yali Friedman

Articles

The ability to pick biotech talent: Being a better interviewer moves ‘you’ up the ladder	PDF
David G Jensen

How the UN’s anti-biotech policies worsen global warming	PDF
Henry I Miller

Building a conducive environment for life science-based entrepreneurship and industry clusters	PDF
Mark J Ahn, Michael Meeks

Cloning an industry: Strategy typologies of Shanghai biotechnology companies	PDF
Ken Malone, Brent Hales, Justin Chan, Monica Love, Jeremiah Rayner

Biotechnology in India: Public–private partnerships	PDF
Viren Konde

Biogenerics 2007: How far have we come?	PDF
John Tucker, Seth Yakatan, Stan Yakatan

Monoclonal antibody therapeutics: Leading companies to maximise sales and market share	PDF
Karl Ziegelbauer, David R Light

Globalising clinical development in Japan	PDF
Yorozu Tabata, Chris Albani

From the Classroom

Bioentrepreneurship education programmes in the United States	PDF
Arlen D Meyers, Patrick Hurley

Legal and Regulatory Updates

Legal and regulatory update	PDF
John Wilkinson

3 Comments/

0 Likes

/0 Tweets/in General Biotechnology

January 2, 2008

02 Jan 2008

Drug Patent Expirations in January 2008

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in January 2008
*Drugs may be
covered by multiple patents

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
CARDIOLITE	Bristol Myers Squibb	technetium tc-99m sestamibi kit	4,988,827	JAN 29,2008
CHILDREN’S ADVIL	Wyeth Cons	ibuprofen	4,788,220	JAN 08,2008
COVERA-HS	Gd Searle Llc	verapamil hydrochloride	5,200,196	JAN 22,2008
DEPAKOTE	Abbott	divalproex sodium	4,988,731	JAN 29,2008
DEPAKOTE	Abbott	divalproex sodium	5,212,326	JAN 29,2008
DEPAKOTE CP	Abbott	divalproex sodium	4,988,731	JAN 29,2008
DEPAKOTE CP	Abbott	divalproex sodium	5,212,326	JAN 29,2008
DEPAKOTE ER	Abbott	divalproex sodium	4,988,731	JAN 29,2008
DEPAKOTE ER	Abbott	divalproex sodium	5,212,326	JAN 29,2008
METROGEL-VAGINAL	Graceway	metronidazole	5,840,744	JAN 15,2008
MIRALUMA	Bristol Myers Squibb	technetium tc-99m sestamibi kit	4,988,827	JAN 29,2008
TECZEM	Biovail	diltiazem malate; enalapril maleate	4,983,598	JAN 08,2008